A Reversibly Thermoresponsive, Theranostic Nanoemulgel for Tacrolimus Delivery to Activated Macrophages: Formulation and In Vitro Validation
Despite long-term immunosuppression, organ transplant recipients face the risk of immune rejection and graft loss. Tacrolimus (TAC, FK506, Prograf<sup>®</sup>) is an FDA-approved keystone immunosuppressant for preventing transplant rejection. However, it undergoes extensive first-pass metabolism and...
Збережено в:
| Автори: | , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
MDPI AG
2023-09-01
|
| Серія: | Pharmaceutics |
| Предмети: | |
| Онлайн доступ: | https://www.mdpi.com/1999-4923/15/10/2372 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|